New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
10:02 EDTKPTIKaryopharm enters into preferred provider agreement with Clinipace Worldwide
Clinipace Worldwide announced that Karyopharm Therapeutics has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. As part of a long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
10:18 EDTKPTIKaryopharm management to meet with JMP Securities
Subscribe for More Information
December 12, 2014
08:16 EDTKPTIKaryopharm sell-off overdone, says JMP Securities
Subscribe for More Information
December 11, 2014
16:30 EDTKPTIOn The Fly: Closing Wrap
Subscribe for More Information
08:10 EDTKPTIKaryopharm initiates third registration-directed clinical trial of Selinexor
Karyopharm Therapeutics announced the initiation of the SADAL study, or Selinexor and Dexamethasone in Aggressive Lymphoma, a registration-directed, Phase 2b study of Selinexor, or KPT-330, in patients with relapsed/refractory diffuse large B-cell lymphoma, or DLBCL. This randomized, multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export/SINE compounds, is being evaluated as a single agent in combination with dexamethasone for supportive care and is expected to enroll approximately 200 patients in approximately 90 sites worldwide. Karyopharm has received Orphan Drug Designation from the FDA and European Medicines Agency, or EMA, for Selinexor for the treatment of patients with DLBCL. This open-label Phase 2b study will evaluate the safety and efficacy of high dose versus mid dose Selinexor in combination with low dose dexamethasone for supportive care, each given orally to approximately 200 patients with relapsed/refractory DLBCL. Overall response rate, or ORR, is the primary endpoint. The study is expected to take approximately two years to complete and is intended to support accelerated regulatory approval. This study was designed in consultation with the FDA and on the basis of data from Karyopharm's ongoing Phase 1 study of Selinexor in patients with advanced hematologic malignancies.
December 9, 2014
10:19 EDTKPTIHigh option volume stocks
Subscribe for More Information
10:08 EDTKPTIHigh option volume stocks
Subscribe for More Information
December 8, 2014
13:03 EDTKPTIKaryopharm reports positive combination data for Selinexor
Subscribe for More Information
December 7, 2014
14:48 EDTKPTIKaryopharm to hold an investor dinner and a clinical data presentation
Investor Dinner and a clinical data presentation being held in conjunction with the American Society of Hematology's 56th Annual Meeting in San Francisco on December 8 at 10:15 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use